Our approach, crafted by a team of Functional Medicine Experts, goes beyond a one-size-fits-all prescription
Trial-Reported Endpoints by Phase Trial Lancet 2021 Phase 2 Duration 26 weeks Population Overweight/obese, no T2D (n=706) Mean Weight Loss 10.8% at 4.5 mg vs 3.0% placebo Trial Lancet 2023 Phase 2 Duration 32 weeks Population T2D + obesity (n=92) Mean Weight Loss 8.1% cagrilintide alone
Its not an aid-all, but a potential tool
PubMed Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A.L., Kleinman, H.K
DEREK MUNRO: And whats your ideal White House card look like
The lack of FDA approval for human use and the need for higher doses in some experimental settings underscore the importance of evaluating safety and efficacy under strict medical supervision